Structure via PubChem · Public domain (PubChem)
vincristine
Sign in to saveAlso known as 22-oxovincaleukoblastine, kyocristine, leurocristine sulfate, NSC-67574, Oncovin®, leurocristine, Leurocristine, Vincristin
Vincristine, also known as leurocristine and sold under the brand name Oncovin among others, is a chemotherapy medication used to treat a number of types of cancer. This includes acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin lymphoma, neuroblastoma, and small cell lung cancer among others. It is given intravenously.
Key facts
- Drug.width
- 240
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461759697
- Drug.image
- Vincristine.svg
- Drug.image_class
- skin-invert-image
- Drug.bioavailability
- n/a (not reliably absorbed by the GI tract)
- Drug.protein_bound
- ~44%
- Drug.metabolism
- Liver, mostly via CYP3A4 and CYP3A5
- Drug.elimination_half life
- 19 to 155 hours (mean: 85 hours)
- Drug.excretion
- Faeces (70–80%), urine (10–20%)
- Drug.IUPHAR_ligand
- 6785
- Drug.CAS_number
- 57-22-7
- Drug.PubChem
- 5978
- Drug.DrugBank
- DB00541
- Drug.ChemSpiderID
- 5758
- Drug.UNII
- 5J49Q6B70F
- Drug.KEGG
- D08679
via Wikipedia infobox
Chemical data
- Formula
- C46H56N4O10
- Molecular weight
- 825 g/mol
- IUPAC name
- methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
- SMILES
- CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
- InChIKey
- OGWKCGZFUXNPDA-XQKSVPLYSA-N
- XLogP
- 2.8
- Polar surface area
- 171 Ų
- H-bond donors
- 3
- H-bond acceptors
- 12
- Formal charge
- 0
via PubChem
Research
35,867 papers- Vincristine therapy.New York state journal of medicine · 1967
- Vincristine in Cancer Therapy: Mechanisms, Efficacy, and Future Perspectives.Current medicinal chemistry · 2025
- Preventing vincristine sulfate medication errors.Oncology nursing forum · 2004
- Vincristine neurotoxicity.The New England journal of medicine · 1972
- Vincristine neurotoxicity.The Medical journal of Australia · 1986
via PubMed
~11 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Side effects
- Mechanism of action
- Chemistry
- History
- Society and culture
- Suppliers
- Shortage
- Controversy
- Pharmaceutical bioprospecting
- Vincristine and confusion with other drugs in administration
- Research
- References
Vincristine, also known as leurocristine and sold under the brand name Oncovin among others, is a chemotherapy medication used to treat a number of types of cancer. This includes acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin lymphoma, neuroblastoma, and small cell lung cancer among others. It is given intravenously.
Most people experience some side effects from vincristine treatment. Commonly it causes a change in sensation, hair loss, constipation, difficulty walking, and headaches. Serious side effects may include neuropathic pain, lung damage, or low white blood cells which increases the risk of infection. Use during pregnancy may result in birth defects. It works by stopping cells from dividing properly. It is vital that it not be given intrathecally, as this may kill.
Excerpted from Wikipedia’s “vincristine” article, available under the CC BY-SA 4.0 licence.